Metabolic diseases such as Type 2 diabetes (T2D) and obesity represent a growing public health problem world-wide. They are characterized by several metabolic abnormalities leading to degenerative organic complications including cardiovascular diseases and cognitive decline. They constitute a socio-economic burden in terms of quality of life, disability, mortality and health cost. T2D and Alzheimer’s disease (AD) are complex diseases with a high genetic component. They shared common genes and variants.
The aim of the present project is to determine the genetic profile of 250 Tunisian individuals classified in different categories: patients with obesity, patients with monogenic diabetes, patients with AD, patients with T2D + AD and healthy controls.
The whole exome sequencing (WES) represents a valuable tool to explore T2D-AD common genetic background in the Tunisian population and to identify new genetic biomarkers. In addition, WES plays a crucial role in the investigation of monogenic diabetes and obesity. It allows the discovery of novel genetic mutations, thus expanding our understanding of the genetic basis of these diseases and contributes to the development of new therapies.
The period of the project is from October 2023 to December 2025.
